Statiny i ostryy koronarnyy sindrom: obosno-vanie, tselesoobraznost' i taktika lecheniya patsientov


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review presents the data from studies of statins in acute coronary syndrome (ACS). Based on results of studies, pleiotropic and lipid mechanisms of action of statins in ACS with regard to the development of cardiovascular complications are analyzed. The practical aspects of treatment with statins at the early stages of hospitalization of patients with ACS are discussed.

Full Text

Restricted Access

References

  1. Dupuis J. Mechanisms of acute coronary syndromes and the potential role of statins. Atherosclerosis Supplements 2001;2(1):9-14.
  2. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
  3. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-18.
  4. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
  5. de Lemos JA, Blazing MA, Wiviott SD, et al. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes Phase Z of the A to Z Trial. JAMA 2004;292:1307-16.
  6. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-78.
  7. Di Sciascio G, Patti G, Pasceri V, et al. Effcacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. J Am Coll Cardiol 2009; 548:558-65.
  8. Kim JC, Kim J, Choi D, et al. Efficacy of High-Dose Atorvastatin Loading Before Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. The STATIN STEMI Trial. J ACC Cardiovasc Interv 2010;3(3):332-39.
  9. Pitt B, Loscalzo J, Monyak J, et al. Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). Am J Cardiol 2012;109:1239-46.
  10. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005;96(5A):24F-33F.
  11. Волков В.И., Строна В.И. Статины при остром коронарном синдроме // Медицина неотложных состояний 2007. Т. 3. № 10. С. 26-32.
  12. Manuel D, Kwong K, Tanuseputro P. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ;doi: 10.1136/bmj.38849.487546.DE.
  13. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-83.
  14. Aikawa M, Rabkin E, Voglic SJ, et al. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circulat Res 1998;83:1015-26.
  15. Aikawa M, Voglic SJ, Sugiyama S, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999; 100:1215-22.
  16. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Amer Coll Cardiology 1998;32:2057-64.
  17. Alaei P, MacNulty EE, Ryder NS. Inhibition of protein prenylation down-regulates signaling by inflammatory mediators in human keratinocytes. Biochem Biophys Res Commun 1996; 222:133-38.
  18. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83:490-500.
  19. Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after with drawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000;102:3104-10.
  20. Ni W, Egashira K, Kataoka C, et al. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circulat Res 2001;89:415-21.
  21. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-78.
  22. Holm T, Andreassen AK, Ueland T, et al. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Amer J Cardiology 2001;87:815-18.
  23. Weitz-Shmidt G, Welzenbach K, Brinkmann, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-92.
  24. Stone PH, Lloyd-Jones DM, Kinlay S, et al. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study. Circulation 2005;111:1747-55.
  25. Colli S, Eligini S, Lalli M, et al. Statins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997;17:265-72.
  26. Ferro D, Basili S, Alessandri C, et al. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 2000; 149:111-16.
  27. Undas A, Brummel KE, Musial J, et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, factor XIII and by enhancing factor Va inactivation. Circulation 2001;103:2248-53.
  28. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Amer Coll Cardiology 1999;33:1294-304.
  29. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:247-51.
  30. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-90.
  31. Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 1998;335:1-13.
  32. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002;105:3017-24.
  33. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Aktpathway. J Clin Invest 2001;108:391-97.
  34. EAS/ESC Guidelines for the management of dyslipidemias. Eur Heart J 2011;32:1769-818.
  35. Гиляревский С.Р., Орлов В.А., Кузьмина И.М. Тактика снижения уровня холестерина липопротеинов низкой плотности в крови у больных острым коронарным синдромом: как низко, как быстро, чем и зачем? // Кардиосоматика 2012. Т. 3. № 2. С. 3-6.
  36. Morrissey RP, Diamond GA, Kaul S. Statins in acute coronary syndromes. Do the guideline recommendations match the evidence? J Am Coll Cardiol 2009;54:425-33.
  37. Colivicchi F, et al. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes. Int J Cardiol 2010;doi: 10.1016/j.ijcard.2010.07.006.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies